title: Serum amino acids, central monoamines, and hormones in drug-naive, drug-free, and neuroleptic-treated schizophrenic patients and healthy subjects.
abstract: Basal serum amino acids (including central monoamine precursors), central monoamines, and hormones were studied in schizophrenic patients (drug-naive; n = 20; drug-withdrawn for 3 or more days, n = 67; neuroleptic-treated, n = 23) and healthy subjects (n = 90) to answer the following questions: (1) Do neuroleptic-withdrawn and neuroleptic-naive patients differ on these serum measures? (2) What are the effects of neuroleptic treatment on these measures? (3) On which variables do drug-free and neuroleptic-treated patients differ? Because serum amino acid, central monoamine, and hormone levels were similar in drug-naive and drug-withdrawn patients, data from these groups ("drug-free") were combined and compared to those of healthy subjects and neuroleptic-treated patients. Asparagine, citrulline, phenylalanine, and cysteine were higher, while tyrosine, tryptophan, and the ratio of tryptophan to competing amino acids were significantly lower in drug-free schizophrenic patients than in healthy subjects. Dopamine was increased, and melatonin and thyroid hormones were decreased in drug-free schizophrenic patients compared to healthy subjects. Norepinephrine, epinephrine, and prolactin were higher in neuroleptic-treated men compared to drug-free male patients or healthy men. These results are consistent with the hypothesis of dopaminergic overactivity in schizophrenia, which might be caused by altered amino acid precursor availability and could be related to the decrease in melatonin and reduction in thyroid hormone levels.
authors.affiliation: Neurochemistry Laboratories, Rheinische Friedrich-Wilhelms-Universität, Bonn, Germany.
authors.forename: M L
authors.initials: ML
authors.lastname: Rao
authors.forename: G
authors.initials: G
authors.lastname: Gross
authors.forename: B
authors.initials: B
authors.lastname: Strebel
authors.forename: P
authors.initials: P
authors.lastname: Bräunig
authors.forename: G
authors.initials: G
authors.lastname: Huber
authors.forename: J
authors.initials: J
authors.lastname: Klosterkötter
mesh_terms: D000328:Adult; D000596:Amino Acids / Q000097:blood*; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001921:Brain / Q000187:drug effects*; D005260:Female; D006728:Hormones / Q000097:blood*; D006801:Humans; D008297:Male; D018377:Neurotransmitter Agents / Q000097:blood*; D017981:Receptors, Neurotransmitter / Q000187:drug effects*; D012559:Schizophrenia / Q000097:blood / Q000188:drug therapy*; D012565:Schizophrenic Psychology; D013375:Substance Withdrawal Syndrome / Q000097:blood
chemical_list: D000596:Amino Acids; D014150:Antipsychotic Agents; D006728:Hormones; D018377:Neurotransmitter Agents; D017981:Receptors, Neurotransmitter